A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies
Zeidan A, Cook R, Bordoni R, Asatiani E, Zhou G, Faivre T, Byrne M, Savona M. A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies. Blood 2017, 130: 640. DOI: 10.1182/blood.v130.suppl_1.640.640.Peer-Reviewed Original ResearchAdvanced acute myeloid leukemiaMDS/MPNAdvanced hematologic malignanciesOverall response rateHigh-risk myelodysplastic syndromePhase 1/2 studyComplete responseIncyte CorporationMyelodysplastic syndromeCombination therapyMultiple myelomaHematologic malignanciesData cutoffAdverse eventsStandard therapySpeakers bureauJAK/STAT pathwayPreliminary safetyDisease progressionEfficacy dataMorphologic leukemia-free stateOngoing phase 1/2 studyJAK1 inhibitorAdvisory CommitteeAdvanced myeloid malignancies